Download PDF
Thromb Haemost 2022; 122(10): 1794-1803
DOI: 10.1055/a-1798-2116
Stroke, Systemic or Venous Thromboembolism

Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus

Krishna Roy Chowdhury
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
2   Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
,
Jonathan Michaud
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
,
Oriana Hoi Yun Yu
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
3   Division of Endocrinology, Jewish General Hospital, Montreal, Québec, Canada
,
Hui Yin
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
,
Laurent Azoulay 
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
2   Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
4   Gerald Bronfman Department of Oncology, McGill University, Montreal, Québec, Canada
,
Christel Renoux 
1   Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
2   Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada
5   Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Aims To evaluate the effectiveness and safety of apixaban versus rivaroxaban among patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes mellitus (T2DM).

Methods and Results Using the United Kingdom's Clinical Practice Research Datalink linked to the Hospital Episode Statistics repository, and the Office for National Statistics database, we identified a cohort of patients with NVAF and T2DM newly treated with apixaban or rivaroxaban between 2013 and 2020. Propensity scores with standardized mortality ratio weighting were used to control for confounding. We used weighted Cox proportional hazards models to estimate separately the hazard ratios (HRs) with 95% confidence intervals (CIs) of ischemic stroke, major bleeding, and major adverse limb events associated with the use of apixaban compared with rivaroxaban. We also evaluated whether the risk was modified by age, sex, duration of diabetes, microvascular and macrovascular complications of diabetes, nephropathy, CHA2DS2-VASc and HAS-BLED scores, and by dose (standard vs. low dose).

Results The cohort included 11,561 apixaban and 8,265 rivaroxaban users. Apixaban was associated with a similar risk of stroke (HR: 0.99, 95% CI: 0.79–1.23), and a 32% reduced risk of major bleeding (HR: 0.68, 95% CI: 0.59–0.78), compared with rivaroxaban. The risk of major adverse limb events was similar between apixaban and rivaroxaban (HR: 0.75, 95% CI: 0.54–1.04). Overall, the risk of ischemic stroke and major bleeding was consistent in stratified analyses.

Conclusion Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke and a lower risk of major bleeding compared with rivaroxaban.

Keywords

nonvalvular atrial fibrillation - type 2 diabetes - apixaban - rivaroxaban - bleeding - stroke

Supplementary Material



Publication History

Received: 10 December 2021

Accepted: 13 March 2022

Accepted Manuscript online:
15 March 2022

Article published online:
13 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22 (08) 983-988
    CrossrefPubMedGoogle Scholar
  • 2 Xiong Z, Liu T, Tse G. et al. A machine learning aided systematic review and meta-analysis of the relative risk of atrial fibrillation in patients with diabetes mellitus. Front Physiol 2018; 9: 835
    CrossrefPubMedGoogle Scholar
  • 3 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69 (06) 546-554
    CrossrefPubMedGoogle Scholar
  • 4 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
    CrossrefPubMedGoogle Scholar
  • 5 Bansilal S, Bloomgarden Z, Halperin JL. et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015; 170 (04) 675-682 .e8
    CrossrefPubMedGoogle Scholar
  • 6 Brambatti M, Darius H, Oldgren J. et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol 2015; 196: 127-131
    CrossrefPubMedGoogle Scholar
  • 7 Ezekowitz JA, Lewis BS, Lopes RD. et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015; 1 (02) 86-94
    CrossrefPubMedGoogle Scholar
  • 8 Plitt A, Ruff CT, Goudev A. et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol 2020; 304: 185-191
    CrossrefPubMedGoogle Scholar
  • 9 Coleman CI, Bunz TJ, Eriksson D, Meinecke AK, Sood NA. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabet Med 2018; 35 (08) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 10 Rustem Gulluoglu F, Souverein PC, van den Ham HA, de Boer A, Komen J. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2021; 30 (10) 1293-1320
    CrossrefPubMedGoogle Scholar
  • 11 Chan Y-H, Lee H-F, Li P-R. et al. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol 2020; 19 (01) 63
    CrossrefPubMedGoogle Scholar
  • 12 Russo V, Attena E, Rago A. et al. Clinical outcome of edoxaban vs. vitamin K antagonists in patients with atrial fibrillation and diabetes mellitus: results from a multicenter, propensity-matched, real-world cohort study. J Clin Med 2020; 9 (06) 1621
    CrossrefPubMedGoogle Scholar
  • 13 Baker WL, Beyer-Westendorf J, Bunz TJ. et al. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diabetes Obes Metab 2019; 21 (09) 2107-2114
    CrossrefPubMedGoogle Scholar
  • 14 Menichelli D, Del Sole F, Di Rocco A. et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother 2021; 7 (FI1): f11-f19
    CrossrefPubMedGoogle Scholar
  • 15 Lip GYH, Keshishian AV, Kang AL. et al. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clin Proc 2020; 95 (05) 929-943
    CrossrefPubMedGoogle Scholar
  • 16 Herrett E, Gallagher AM, Bhaskaran K. et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44 (03) 827-836
    CrossrefPubMedGoogle Scholar
  • 17 Wolf A, Dedman D, Campbell J. et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol 2019; 48 (06) 1740-1740g
    CrossrefPubMedGoogle Scholar
  • 18 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69 (01) 4-14
    CrossrefPubMedGoogle Scholar
  • 19 NHS.. Hospital Episode Statistics. 2021. Accessed July 27, 2021 at: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics
    PubMedGoogle Scholar
  • 20 CPRD.. CPRD linked data. Accessed July, 29, 2021 at: https://www.cprd.com/linked-data#Death%20Registration%20data
    PubMedGoogle Scholar
  • 21 Office for National Statistics.. User guide to mortality statistics. Accessed July 27, 2021 at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/userguidetomortalitystatisticsjuly2017
    PubMedGoogle Scholar
  • 22 Chisholm J. The Read clinical classification. BMJ 1990; 300 (6732): 1092
    CrossrefPubMedGoogle Scholar
  • 23 NHS.. SNOMED CT. Accessed March 29, 2022 at: https://digital.nhs.uk/services/terminology-and-classifications/snomed-ct 2020
    PubMedGoogle Scholar
  • 24 Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 2019; 367: l5657
    CrossrefPubMedGoogle Scholar
  • 25 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    Google Scholar
  • 26 Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non–vitamin K antagonist oral anticoagulants: A review. JAMA Cardiol 2017; 2 (04) 442-448
    CrossrefPubMedGoogle Scholar
  • 27 Kiers L, Davis SM, Larkins R. et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992; 55 (04) 263-270
    CrossrefPubMedGoogle Scholar
  • 28 Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 1996; 27 (02) 210-215
    CrossrefPubMedGoogle Scholar
  • 29 Alwafi H, Wei L, Naser AY. et al. Trends in oral anticoagulant prescribing in individuals with type 2 diabetes mellitus: a population-based study in the UK. BMJ Open 2020; 10 (05) e034573
    CrossrefPubMedGoogle Scholar
  • 30 Haastrup SB, Hellfritzsch M, Rasmussen L, Pottegård A, Grove EL. Use of non-vitamin K antagonist oral anticoagulants 2008-2016: a Danish Nationwide Cohort study. Basic Clin Pharmacol Toxicol 2018; 123 (04) 452-463
    CrossrefPubMedGoogle Scholar
  • 31 Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. Eur J Clin Pharmacol 2017; 73 (11) 1417-1425
    CrossrefPubMedGoogle Scholar
  • 32 Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 2017; 83 (09) 2096-2106
    CrossrefPubMedGoogle Scholar
  • 33 Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med 2020; 172 (07) 463-473
    CrossrefPubMedGoogle Scholar
  • 34 Lip GYH, Keshishian A, Li X. et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018; 49 (12) 2933-2944
    CrossrefPubMedGoogle Scholar
  • 35 López-López JA, Sterne JAC, Thom HHZ. et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
    CrossrefPubMedGoogle Scholar
  • 36 Ray WA, Chung CP, Stein CM. et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA 2021; 326 (23) 2395-2404
    CrossrefPubMedGoogle Scholar
  • 37 Frost C, Song Y, Barrett YC. et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: 179-187
    PubMedGoogle Scholar
  • 38 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    Google Scholar
  • 40 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
    CrossrefPubMedGoogle Scholar
  • 42 Nativel M, Potier L, Alexandre L. et al. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovasc Diabetol 2018; 17 (01) 138
    CrossrefPubMedGoogle Scholar
  • 43 Anand SS, Caron F, Eikelboom JW. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol 2018; 71 (20) 2306-2315
    CrossrefPubMedGoogle Scholar
  • 44 Overvad TF, Skjøth F, Lip GY. et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke 2015; 46 (08) 2168-2174
    CrossrefPubMedGoogle Scholar
  • 45 Fangel MV, Nielsen PB, Kristensen JK. et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: a Danish cohort study. Circ Arrhythm Electrophysiol 2019; 12 (05) e007030
    CrossrefPubMedGoogle Scholar
  • 46 NICE.. Atrial fibrillation: management. Published 2021. Accessed July 27, 2021 at: https://www.nice.org.uk/guidance/ng196
    PubMedGoogle Scholar
  • 47 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar